Cancer Genetics (Vyant Bio) Acquires StemoniX
March 31, 2021
Cancer Genetics, Inc. completed a merger with StemoniX, Inc. and renamed the combined company Vyant Bio, Inc., with the new ticker VYNT on Nasdaq. StemoniX will operate as a wholly-owned subsidiary as the combined business integrates human iPSC-derived biology, software and preclinical capabilities to create a unified drug discovery platform.
- Buyers
- Vyant Bio, Inc. (formerly Cancer Genetics, Inc.)
- Targets
- StemoniX, Inc.
- Sellers
- Former holders of StemoniX common stock, preferred stock, convertible notes and certain warrants
- Industry
- Biotechnology
- Location
- Minnesota, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
HiberCell Acquires Genuity Science, Inc.
August 16, 2021
Biotechnology
HiberCell, a clinical-stage oncology company, acquired Genuity Science, a genomics and multi‑omic analytics company with an advanced AI/ML platform, to integrate next‑generation computational capabilities into its translational oncology efforts. The stock acquisition brings Genuity and its subsidiaries into HiberCell, provides approximately $100 million in cash and existing partnership earnouts, and is intended to accelerate HiberCell's clinical programs and expand its preclinical pipeline.
-
OncoCyte Corporation Acquires Insight Genetics
January 10, 2020
Healthcare Services
OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.
-
Vertex Pharmaceuticals Acquires ViaCyte for $320M
July 11, 2022
Biotechnology
Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.
-
Astellas Pharma Acquires Xyphos Biosciences
December 26, 2019
Biotechnology
Astellas Pharma has acquired Xyphos Biosciences, gaining Xyphos' ACCEL convertible-CAR technology platform and immuno-oncology talent. The deal included $120 million paid at closing and potential milestone payments bringing the total transaction value to up to $665 million.
-
BioIVT Acquires ZenBio
August 21, 2024
Healthcare Services
BioIVT has acquired ZenBio, a Durham-based provider of advanced cell products and biospecimen services, to expand its skin-based expertise, primary cell and exosome isolation capabilities, and blood product offerings for pharmaceutical and cosmetics research. The deal strengthens BioIVT's service portfolio and complements recent integrations to accelerate support for drug discovery and cosmeceutical development; financial terms were not disclosed.
-
StemBioSys Acquires Majority Stake in Cartox
January 8, 2020
Biotechnology
San Antonio-based StemBioSys acquired a majority stake in Ann Arbor startup Cartox, obtaining control with plans to purchase the remaining equity subject to milestones. The deal brings Cartox's cardiotoxicity imaging and assay capabilities together with StemBioSys's CELLvo extracellular matrix technology to accelerate commercial development of pre-clinical cardiac safety and efficacy screening solutions.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.